SAN DIEGO--(BUSINESS WIRE)--May 15, 2018--
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic
testing solutions, cellular-based virology assays and molecular
diagnostic systems, announced today that it will present at the UBS
Global Healthcare Conference at the Grand Hyatt New York hotel in New
York, New York on Wednesday, May 23, 2018.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present on Wednesday, May 23,
2018 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) with a
question-and-answer session scheduled immediately following the
presentation. During the presentation, the company will discuss business
and financial developments and trends. The company's statements may
contain or constitute material information that has not been previously
disclosed.
A live webcast and audio archive of the presentation will be available
via the Investor Relations section of the company’s website at http://ir.quidel.com
or by clicking the link below:
https://cc.talkpoint.com/ubsx001/052118a_as/?entity=37_XCP8GVS
Participants should allow approximately five to ten minutes prior to the
presentation's start time to visit the site and download any streaming
media software needed to listen to the Internet webcast. A replay of the
webcast will also be available on the company’s website for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as
well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic
brands, Quidel’s products aid in the detection and diagnosis of many
critical diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease
and fecal occult blood. Quidel's recently acquired Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC), offering
a diverse immunoassay menu in a variety of tests to provide healthcare
providers with diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s research
and development engine is also developing a continuum of diagnostic
solutions from advanced immunoassay to molecular diagnostic tests to
further improve the quality of healthcare in physicians’ offices,
hospital and reference laboratories, and other alternate sites, like
urgent care centers and retail clinics, where healthcare is provided.
For more information about Quidel’s comprehensive product portfolio,
visit quidel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180515006666/en/
Source: Quidel Corporation
Quidel Contact:
Quidel Corporation
Randy Steward
Chief
Financial Officer
(858) 552-7931
or
Media and Investors
Contact:
Quidel Corporation
Ruben Argueta
(858) 646-8023
rargueta@quidel.com